Gazyvaro
Showing 1 - 25 of 34
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)
Not yet recruiting
- Follicular Lymphoma
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Richter's Transformation
- Glofitamab
- +4 more
-
Boston, Massachusetts
- +1 more
Sep 12, 2023
Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib and obinutuzumab
-
Milano, MI, ItalyStrategic Research Program on CLL
Apr 2, 2022
Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)
Recruiting
- Large B-cell Lymphoma
- mosunetuzumab
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jul 21, 2022
Primary CNS Lymphoma Trial in Stuttgart (Venetoclax, Obinutuzumab)
Terminated
- Primary CNS Lymphoma
-
Stuttgart, Baden-Württemberg, GermanyKlinikum Stuttgart
Jan 18, 2022
Lymphoma, Non-Hodgkin Trial in Mainz (Obinutuzumab and Pixantrone)
Completed
- Lymphoma, Non-Hodgkin
- Obinutuzumab and Pixantrone
-
Mainz, RLP, GermanyDepartment of Hematology, Oncology and Pneumology; University Me
Mar 30, 2022
Lupus Nephritis, Systemic Lupus Erythematosus (SLE) Trial in Paris (Obinutuzumab administration, Administration of
Recruiting
- Lupus Nephritis
- Systemic Lupus Erythematosus (SLE)
- Obinutuzumab administration
- +2 more
-
Paris, FranceInternal medicine, Cochin hospital, APHP
Dec 9, 2021
Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)
Active, not recruiting
- Chronic Lymphoid Leukemia
- Bendamustine
- +3 more
-
Dresden, Germany
- +16 more
Nov 8, 2022
Lymphoma, Large B-Cell, Diffuse Trial in Austria (Venetoclax, Obinutuzumab)
Completed
- Lymphoma, Large B-Cell, Diffuse
-
Graz, Austria
- +5 more
Feb 15, 2022
Colorectal Cancer Trial in Worldwide (Obinutuzumab, Atezolizumab, Cibisatamab)
Active, not recruiting
- Colorectal Cancer
- Obinutuzumab
- +3 more
-
Los Angeles, California
- +12 more
Aug 19, 2022
Chronic Lymphocytic Leukemia Trial in Germany (Tirabrutinib, Idelalisib, Obinutuzumab)
Completed
- Chronic Lymphocytic Leukemia
- Tirabrutinib
- +2 more
-
Frankfurt, Brandenburg, Germany
- +13 more
Dec 24, 2021
Chronic Lymphocytic Leukemia Trial in Germany (Tirabrutinib, Entospletinib, Obinutuzumab)
Completed
- Chronic Lymphocytic Leukemia
- Tirabrutinib
- +2 more
-
Aschaffenburg, Germany
- +14 more
Dec 17, 2021
Chronic Lymphocytic Leukemia Trial in Germany (Obinutuzumab, Venetoclax, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia
- Obinutuzumab
- +2 more
-
Bad Saarow, Germany
- +29 more
May 4, 2022
CD20+ Follicular Lymphoma Trial in Worldwide (Duvelisib, Rituximab, Obinutuzumab)
Terminated
- CD20+ Follicular Lymphoma
- Duvelisib
- +2 more
-
Los Angeles, California
- +20 more
Mar 15, 2021
Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)
Recruiting
- Follicular Lymphoma
-
München, Bavaria, Germany
- +39 more
May 19, 2022
B-Cell Chronic Lymphocytic Leukemia Trial in Worldwide (Chlorambucil, Obinutuzumab, Placebo)
Terminated
- B-Cell Chronic Lymphocytic Leukemia
- Chlorambucil
- +4 more
-
Haifa, Israel
- +13 more
Apr 6, 2021
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a Trial in Heidelberg (Standard, Experimental)
Recruiting
- Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
- Standard
- Experimental
-
Heidelberg, GermanyUniversity Hospital Heidelberg
Jul 10, 2022